Weight loss injections — including semaglutide (Ozempic and Wegovy) and liraglutide (Saxenda) — have transformed the treatment of obesity in the UK. These medications, known as GLP-1 receptor agonists, were originally developed for type 2 diabetes but have shown remarkable effectiveness for weight loss, with some patients losing 15–20% of their body weight. Demand in the UK has been extraordinary, creating ongoing supply issues and long NHS waiting lists.
What Are GLP-1 Weight Loss Injections?
GLP-1 (glucagon-like peptide-1) receptor agonists mimic the action of a naturally occurring gut hormone that is released after eating. They work by stimulating insulin release in response to meals (lowering blood sugar), suppressing glucagon (which raises blood sugar), slowing the rate at which the stomach empties (increasing feelings of fullness), and acting on the brain’s appetite centres to reduce hunger and food cravings. The overall result is a significant reduction in food intake and, consequently, body weight.
Ozempic vs Wegovy: What Is the Difference?
Both Ozempic and Wegovy contain semaglutide but are licensed for different purposes in the UK. Ozempic is licensed for type 2 diabetes management and is injected once weekly. It is available on the NHS for eligible diabetic patients. Wegovy contains a higher dose of semaglutide (2.4mg vs Ozempic’s maximum of 2mg) and is specifically licensed for weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related health condition. Wegovy was approved by the MHRA in 2023 and began rolling out on the NHS in 2024 for eligible patients via specialist weight management services.
Saxenda (liraglutide 3mg) is a daily injection also licensed for weight management in the UK. It is available on the NHS for qualifying patients but is less potent than Wegovy in terms of weight loss — clinical trials show average weight loss of around 5–8% of body weight with Saxenda, compared to around 15% with Wegovy.
Mounjaro (Tirzepatide): The Next Generation
Mounjaro (tirzepatide) is the newest and most powerful weight loss injection available in the UK. Unlike GLP-1 receptor agonists, tirzepatide is a dual GIP and GLP-1 receptor agonist — acting on two gut hormone pathways simultaneously. Clinical trials (the SURMOUNT programme) showed average weight loss of up to 20–22% of body weight at the highest dose — exceeding any previously available medication. Mounjaro was approved by the MHRA for weight management in the UK in 2023 and is available privately. NHS availability via weight management services is being phased in. It is also licensed in the UK as Mounjaro for type 2 diabetes.
Who Qualifies for NHS Weight Loss Injections?
NHS access to weight loss injections in England is currently limited due to demand and cost. NICE approved Wegovy (semaglutide 2.4mg) for NHS use in 2023, for adults with a BMI of 35 or above plus at least one weight-related condition (such as type 2 diabetes, hypertension, or sleep apnoea), or BMI 30–34.9 with specific clinical need. The NHS rollout is being managed through specialist NHS weight management services over a two-year initiation period, with a maximum treatment duration of two years. For type 2 diabetes, Ozempic is available on NHS prescription from your GP for eligible patients meeting clinical criteria.
Private Weight Loss Injections in the UK
Due to long NHS waiting lists, many people in the UK are accessing weight loss injections privately through online pharmacies, private clinics, and GP services. Private prescriptions for Wegovy, Saxenda, and Mounjaro are widely available, though costs can be significant — Wegovy costs around £200–£280 per month privately, Saxenda around £200–£250 per month, and Mounjaro £130–£200 per month depending on dose. Private prescribers are required to conduct a full medical consultation, assess BMI, take a medical history, and monitor patients during treatment. The Care Quality Commission (CQC) regulates private prescribers in England.
How Effective Are Weight Loss Injections?
Clinical trial results for weight loss injections are impressive. In the STEP 1 trial, weekly semaglutide 2.4mg (Wegovy) produced an average weight loss of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. In the SURMOUNT-1 trial, tirzepatide 15mg (Mounjaro) produced average weight loss of 20.9%. Weight loss of this magnitude significantly improves blood pressure, cholesterol, blood sugar control, sleep apnoea, joint pain, and quality of life. Semaglutide has also demonstrated a 20% reduction in cardiovascular events (heart attack and stroke) in overweight and obese patients with established cardiovascular disease (SELECT trial).
Side Effects of Weight Loss Injections
The most common side effects are gastrointestinal and include nausea, vomiting, diarrhoea, constipation, and stomach discomfort. These are usually most pronounced in the early weeks and improve as the dose is gradually increased. Other reported side effects include headache, fatigue, and injection site reactions. Serious but rare side effects include pancreatitis, gallbladder disease (gallstones), and for GLP-1 agonists, a theoretical risk of thyroid tumours (observed in animal studies; no confirmed increased risk in humans but GLP-1 agonists are contraindicated in those with a personal or family history of medullary thyroid carcinoma). The rapid weight loss can cause muscle loss alongside fat loss — strength training and adequate protein intake are recommended during treatment.
Weight Regain After Stopping
A key consideration with weight loss injections is that weight typically returns when medication is stopped. In the STEP 4 trial, participants who discontinued semaglutide regained around two-thirds of their lost weight over the following year. This suggests that for many people, GLP-1 agonists may need to be taken long-term — similar to blood pressure or cholesterol medication — rather than as a short-term course. The NHS currently limits treatment to two years, though this is under review.
Important: Weight loss injections are prescription-only medications and must be used under medical supervision. They are not suitable for everyone. Speak to your GP or a qualified healthcare professional to discuss whether these medications are appropriate for you.
Related Health Guides on YourHealthXpert
Explore these related NHS-aligned health guides on conditions connected to this topic:
- Type 2 Diabetes — GLP-1 agonists like semaglutide significantly improve blood sugar control
- High Blood Pressure — weight loss through GLP-1 agonists substantially reduces blood pressure
- High Cholesterol — improved with weight loss and GLP-1 therapy
- Liver Disease and NAFLD — semaglutide shows strong evidence for improving NASH
- Weight Loss — comprehensive guide to all NHS weight loss options including lifestyle and surgery
- Sleep Apnoea — obesity is the primary cause; weight loss can resolve sleep apnoea